Search Results
Your search for 27 matches 3369 pages
Showing 901 - 950Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
Sacituzumab Govitecan-hziy: Welcome Addition to Advanced Urothelial Cancer Treatments, but Time to Figure Out Sequencing and Combinations
The results of Cohort 1 of the phase II trial TROPHY-U-01 (IMMU-132-06; ClinicalTrials.gov identifier NCT03547973), published in the Journal of Clinical Oncology by Tagawa et al and reviewed in this issue of The ASCO Post, led to the recent accelerated U.S. Food and Drug Administration (FDA)...
Sacituzumab Govitecan-hziy in Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy
In a cohort of the phase II TROPHY-U-01 trial reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, and colleagues, found that the antibody-drug conjugate sacituzumab govitecan-hziy produced durable responses in patients with metastatic...
Reducing Prostate Cancer Disparity by Bringing Care to Underserved Populations
The dire cancer incidence and mortality statistics for Black patients compared with White patients are well known. Collectively, Black individuals have the highest mortality rate and shortest survival of any racial or ethnic group in the United States for most cancers. Black men also have the...
Is Chemotherapy Associated With Complications or Poorer Outcomes Among Women Undergoing Immediate Breast Reconstruction?
In a cohort study reported in JAMA Surgery, Hart et al found that treatment with either neoadjuvant or adjuvant chemotherapy was not associated with an increased risk of complications or poorer patient-reported outcomes in women undergoing mastectomy for breast cancer with immediate breast...
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
In a study reported in The New England Journal of Medicine, Awad et al identified potential mechanisms of acquired resistance to the KRAS G12C inhibitor adagrasib in patients receiving the agent for treatment of KRAS G12C–mutant cancers. As noted by the investigators, clinical trials of the KRAS...
FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma
On July 6, the U.S. Food and Drug Administration (FDA) approved an expanded label for pembrolizumab, an anti–PD-1 agent, as monotherapy for patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation. This approval is based on data from the second...
Recovery of Gonadal Function With PET-Adapted Regimen for Advanced Hodgkin Lymphoma
In a prospective analysis from the phase III Lymphoma Study Association AHL2011 trial reported in the Journal of Clinical Oncology, Demeestere et al found that patients with advanced Hodgkin lymphoma receiving a positron-emission tomography (PET)-adapted regimen had a reduced risk of gonadal...
Humanized CD19-Targeted CAR T-Cell Treatment in Patients With Relapsed or Refractory B-Cell ALL
In a pilot study reported by Myers et al in the Journal of Clinical Oncology, a humanized CD19-targeted chimeric antigen receptor (CAR) T-cell product developed by the investigators (huCART19) was found to produce durable remissions and prolonged CAR T-cell persistence in CAR-naive and CAR-exposed...
Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma
Despite new and effective treatments for melanoma with checkpoint inhibitors and targeted therapies, patients with metastatic melanoma who progress on frontline treatment generally do very poorly. “We really need to make sure we give these patients access to drugs that we know have some efficacy,”...
Efficiency of Virtual Care for Oncology Patients During the COVID-19 Pandemic
In a single-institution study reported in JCO Oncology Practice, Hsiehchen et al found that replacement of in-person with telehealth visits among patients with cancer initiating systemic therapy during the COVID-19 pandemic was not associated with poorer efficiency in components of oncology care or ...
Watch Now: Discussion on Eligibility Criteria and the Impact on Access to Clinical Trials
On Friday, April 9, 2021, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the health-care sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient...
How to Talk With Teens and Young Adults About Their End-of-Life Goals
Although death rates for adolescent and young adults (AYAs) with cancer have been dropping 0.8% a year from 2009 to 2018, cancer remains a leading disease-related cause of death among this patient population. This year, the National Cancer Institute (NCI) estimates that 88,260 AYAs, defined by the...
CheckMate 648: First-Line Nivolumab Regimens Improve Survival in Esophageal Squamous Cell Carcinoma
As first-line treatment of advanced esophageal squamous cell carcinoma, nivolumab-containing regimens improved overall survival over standard-of-care chemotherapy, according to the first results of the global phase III CheckMate 648 trial presented at the 2021 ASCO Annual Meeting by Ian Chau, MD,...
Newly Diagnosed Multiple Myeloma
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on...
Reduced-Dose and Reduced-Volume Radiotherapy Plus Chemotherapy in Newly Diagnosed Patients With Average-Risk Medulloblastoma
As reported in the Journal of Clinical Oncology by Jeff M. Michalski, MBA, MD, and colleagues, the Children’s Oncology Group noninferiority phase III ACNS0331 trial has shown no decrease in event-free survival with reduced radiation boost volume in patients with newly diagnosed, average-risk...
ctDNA and Early Relapse After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma
In a prospective study reported in the Journal of Clinical Oncology, Frank et al found that monitoring of circulating tumor DNA (ctDNA) improved detection of early relapse after axicabtagene ciloleucel infusion in patients with relapsed or refractory large B-cell lymphoma. Study Details A total of...
Adjuvant Metronomic Capecitabine for Locoregionally Advanced Nasopharyngeal Carcinoma
In a Chinese phase III study reported in The Lancet, Chen et al found that the use of adjuvant metronomic capecitabine improved failure-free survival vs observation after definitive chemoradiotherapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma. Study Details In the...
Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML
As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...
Trilaciclib to Reduce Chemotherapy-Induced Bone Marrow Suppression in Extensive-Stage Small Cell Lung Cancer
On February 12, 2021, the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor trilaciclib was approved for use to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide–containing regimen or topotecan-containing regimen for...
Pralsetinib in Advanced RET Fusion–Positive NSCLC: ARROW Trial
As reported in The Lancet Oncology by Justin F. Gainor, MD, and colleagues, an interim analysis of the phase I/II ARROW trial has shown that the oral RET inhibitor pralsetinib produced high response rates in previously treated and treatment-naive patients with advanced RET fusion–positive non–small ...
Cryoablation in Low-Risk Breast Cancers: Minimally Invasive Procedure With Minimal Risk
Cryoablation is emerging as a new alternative to surgical excision for smaller early-stage, low-risk breast cancers in appropriately selected patient populations, according to data presented during the 2021 American Society of Breast Surgeons Annual Meeting.1 Early 3-year results of the multicenter ...
Immunotherapy With Cemiplimab-rwlc Yields Survival Benefit in Advanced Cervical Cancer
The PD-L1 inhibitor cemiplimab-rwlc has become the first immunotherapy to yield a statistically significant and clinically meaningful survival benefit in recurrent or metastatic cervical cancer progressing after first-line platinum-containing chemotherapy. Patients were enrolled irrespective of...
Patient-Reported Outcomes From the IMbrave150 Trial in Advanced Hepatocellular Carcinoma
In an analysis from the phase III IMbrave150 trial reported in The Lancet Oncology, Peter R. Galle, MD, and colleagues found that patients receiving atezolizumab plus bevacizumab had better patient-reported outcomes vs those receiving sorafenib for advanced unresectable or metastatic hepatocellular ...
Addition of Copanlisib to Rituximab Improves Progression-Free Survival in Relapsed Indolent Non-Hodgkin Lymphoma
As reported in The Lancet Oncology by Matthew J. Matasar, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CHRONOS-3 trial has shown that the addition of the pan-class I PI3K inhibitor copanlisib to rituximab significantly improved progression-free survival vs rituximab ...
Nivolumab/Ipilimumab Improves Overall Survival vs Chemotherapy in First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
As reported in The Lancet by Paul Baas, MD, of The Netherlands Cancer Institute, Amsterdam, and colleagues, a prespecified interim analysis in the phase III CheckMate 743 trial has shown improved overall survival with first-line nivolumab/ipilimumab vs platinum-based chemotherapy in unresectable...
Is High Tumor Mutational Burden Predictive of Immune Checkpoint Blockade Efficacy Across All Cancer Types?
In a letter recently published in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, Rousseau and colleagues reported data on the spectrum of benefit from immune checkpoint blockade in hypermutated tumors.1 Indeed, the U.S. Food and Drug Administration (FDA) recently...
Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
In a phase II study (innovaTV 204/GOG-3023/ENGOT-cx6) reported in The Lancet Oncology, Robert L. Coleman, MD, and colleagues found that the antibody-drug conjugate tisotumab vedotin produced durable responses in previously treated patients with recurrent or metastatic cervical cancer. In the...
Global Responses to COVID-19 Pandemic–Related Disruptions in Cancer Care
COVID-19 pandemic–related disruptions in cancer diagnosis, treatment, and research have varied worldwide and so have the responses to those disruptions. During the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care, members of the Global Forum of Cancer...
Adding Targeted Agent to Treatment Shows Significant Benefits in Pediatric Patients With High-Risk Hodgkin Lymphoma
Integrating the antibody-drug conjugate brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma “facilitated significant reduction in radiation exposure and yielded excellent outcomes,” Monika Metzger, MD, MSc, Director for the Central and South...
Inclusion of Patients With Brain Metastases in Phase III Trials in Advanced Breast Cancer, Lung Cancer, and Melanoma
In a study reported in a research letter in JAMA Oncology, Corbett et al found that the majority of phase III trials investigating systemic therapy in patients with advanced lung cancer, breast cancer, and melanoma over the past 20 years have excluded or restricted enrollment of those with brain...
New Web-Based Lesion Selection Tool May Improve Coordination, Performance, and Management of Biopsy Specimens
In a single-institution study reported in the Journal of Immunotherapy and Precision Oncology, Xu et al found that the use of a Web-based lesion selection tool (LST) developed by the research team improved consistency in lesion selection for sequential biopsy. In addition, the tool improved the...
Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer
The first results from the phase III CheckMate 648 study represent significant progress in the treatment of patients with advanced esophageal squamous cell carcinoma. The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced...
New FDA-Approved Oncology Drugs and Label Updates Between May 8, 2020, and May 8, 2021
Over the past year (May 2020–May 2021), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. PEMBROLIZUMAB (KEYTRUDA) in...
Organizations Issue Statement Encouraging Return to HPV Vaccination
Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...
Does the Addition of Bevacizumab to Gemcitabine/Cisplatin for Metastatic Urothelial Carcinoma Improve Survival?
As reported in the Journal of Clinical Oncology by Jonathan E. Rosenberg, MD, and colleagues, the phase III CALGB 90601/Alliance trial has shown no improvement in overall survival with the addition of bevacizumab to gemcitabine/cisplatin in patients with metastatic urothelial carcinoma. Study...
Stereotactic Radiosurgery for Brainstem Metastases
In a systematic review and meta-analysis reported in JAMA Oncology, Chen et al found that stereotactic radiosurgery for brainstem metastases was effective and safe, with outcomes comparable to those observed with stereotactic radiosurgery for nonbrainstem brain metastases. Study Details A...
FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved piflufolastat F-18 injection (Pylarify), an F-18–labeled prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. This is...
Coagulopathy and COVID-19 Infection
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the...
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
On March 26, 2021, idecabtagene vicleucel was approved for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.1,2 Idecabtagene vicleucel is...
First-Line Cemiplimab-rwlc Improves Outcomes vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Ahmet Sezer, MD, of Başkent University, Adana, Turkey, and colleagues, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Fluciclovine F-18 PET/CT vs Conventional Imaging Alone in Guiding Postsurgery Salvage Radiotherapy for Prostate Cancer
In a single-institution phase II/III trial (EMPIRE-1) reported in The Lancet, Ashesh B. Jani, MD, and colleagues found that use of fluciclovine F-18 positron-emission tomography/computed tomography (PET/CT) in addition to conventional imaging to guide postprostatectomy salvage radiotherapy was...
Enfortumab Vedotin-ejfv After PD-1 or PD-L1 Inhibitor Therapy for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
As reported in The Lancet Oncology by Evan Y. Yu, MD, and colleagues, findings in a cohort of the phase II EV-201 study showed a high response rate with the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv in cisplatin-ineligible patients with advanced or metastatic urothelial...
Pembrolizumab Improves Progression-Free Survival vs Brentuximab Vedotin in Relapsed or Refractory Classic Hodgkin Lymphoma
As reported in The Lancet Oncology by John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, and colleagues, an interim analysis of the phase III KEYNOTE-204 trial has shown significantly improved progression-free survival with pembrolizumab vs brentuximab vedotin in patients with...
Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 26, 2021, the peptide-conjugated alkylating...
Ipilimumab Plus Anti–PD-1 Therapy vs Ipilimumab Alone for Patients With Advanced Melanoma Resistant to Anti–PD-1/PD-L1 Monotherapy
In a retrospective cohort study reported in The Lancet Oncology, da Silva et al found that better outcomes were achieved with the combination of an anti–PD-1 agent plus ipilimumab vs ipilimumab alone in patients with advanced melanoma who were resistant to prior anti–PD-1 or anti–PD-L1 ...
ASCO’s President-Elect Focuses on Advancing Equitable Cancer Care Through Innovation
Internationally renowned for his pioneering research in combining high-dose radiation therapy and chemotherapy in the treatment of locally advanced head and neck cancer to improve patient survival, ASCO’s President-Elect Everett E. Vokes, MD, FASCO, is dedicating his tenure as President to...
Dual BRAF/MEK Inhibition Under Study in BRAF V600E–Mutant Gliomas
The combination of dabrafenib plus trametinib led to encouraging and durable responses in patients with low- and high-grade gliomas harboring BRAF V600E mutations, according to the results of the phase II basket study known as ROAR. Results were presented during the virtual edition of the American...
Cardiac Safety, Efficacy of Neoadjuvant Pertuzumab/Trastuzumab for Early-Stage HER2-Positive Breast Cancer
Long-term cardiac safety and efficacy have been confirmed for the combination of pertuzumab plus trastuzumab in patients with early-stage HER2-positive breast cancer, according to the final analysis of the phase II BERENICE trial reported by Chau T. Dang, MD, and colleagues at the ESMO Breast...
